The Calmare Device – MC–5A
The Calmare® MC-5A device is a U.S. FDA 510(k)-cleared and European CE mark-certified pain therapy medical device for the non-invasive treatment of chronic neuropathic and oncologic pain. Treatment using the Calmare device avoids the harmful, potentially fatal, adverse side effects and addictive properties linked to narcotic pain killers.
Conditions Treated : Calmare Device
The Calmare device has been used to successfully treat over 4,000 patients worldwide, where it has been shown to be effective in treating neuropathic and oncologic pain. Conditions treated include:
- Chemotherapy-induced peripheral neuropathy (CIPN)
- Phantom limb syndrome
- Post-surgical neuropathic pain
- Low back pain
- Neck pain
- Reflex sympathetic dystrophy
- Postherpetic neuralgia (PHN)
The Calmare device was developed by Professor Giuseppe Marineo, a researcher and bioengineer and the founder and manager of Delta Research & Development. Delta R&D is the Bioengineering Research Centre affiliated with Tor Vergata University of Rome, Italy.
The device, with a biophysical rather than a biochemical approach, uses a multi-processor able to simultaneously treat multiple pain areas by applying surface electrodes to the skin. The device creates and sends a no-pain signal which becomes the dominant signal received by the brain, thus overriding the pain signal and providing relief for the patient.
The technology was brought to Competitive Technologies, Inc. (OTCQX: CTTC) through the efforts of Prof. Giancarlo Elia Valori of the Italian business development group, Sviluppo Lazio S.p.A. CTTC licensee GEOMC of Korea is manufacturing the device commercially for worldwide sales.
In honor of the technology’s Italian inventor, CTTC chose to call this medical device “Calmare“. Translated from Italian, “calmare” means “to soothe or ease.” Treatment utilizing the Calmare device eases the suffering that patients endure from debilitating pain.